Gemoscan's Chief Naturopath Recognized by Peers With Leadership Award

Gemoscan's Chief Naturopath Recognized by Peers With Leadership Award

TORONTO, Jan. 14, 2013 (GLOBE NEWSWIRE) -- Gemoscan Canada, Inc. (TSX-V:GES)
(MUN:1GE) ("Gemoscan" or the "Company"), a leading owner and marketer of food
sensitivity and dietary management solutions, wishes to congratulate its Chief
Naturopath and Naturopathic Advisor, Mubina Jiwa, N.D., on being recently
awarded a Leadership Pin by Naturopathic Doctors Ontario ("NDO").

In 2011, to mark their 60th Anniversary, NDO began a new tradition of awarding
Leadership Pins to NDs and Corporate Partners who in the course of their years
as members or over the past year have provided their leadership to the
association. This honour was bestowed upon Dr. Jiwa in recognition of her
providing valuable leadership and expertise to the NDO organization in 2012.

"The Leader Pin is a significant award given to influential Naturopathic
Doctors who are members of Naturopathic Doctors Ontario, and who have provided
valuable leadership and expertise to our association," said Elias Markou,
Chair of NDO.

Dr. Jiwa has been with Gemoscan since 2007. Previously, she was Associate
Professor, and is now Assistant Professor, at the Canadian College of
Naturopathic Medicine. She is a member of Naturopathic Doctors Ontario and is
registered with the Board of Directors of Drugless Therapy - Naturopathy. Dr.
Jiwa has collaborated on nutrition-related research projects at the University
of British Colombia and on research projects at the British Colombia
Children's Hospital. Dr. Jiwa's program on immuno food intolerances has been
accredited by the Canadian Council on Continuing Education in Pharmacy. Dr.
Jiwa also manages a private practice in the Greater Toronto Area.

"On behalf of every member of the Gemoscan family, I would like to
congratulate Dr. Jiwa on this wonderful achievement. Her expertise and
integrity are clearly evident in all aspects of her professional life. I am
personally honored to be associated with Dr. Jiwa and look forward to her
ongoing guidance as we continue to build upon Gemoscan's leadership position
in the emerging food intolerance industry," said Brian Kalish, Gemoscan's
President and Chief Executive Officer.

About Gemoscan Canada, Inc.

Gemoscan is an industry leader in food intolerance management and maintains a
first-to- market position with Canada wide distribution through select retail
partners. Founded in 2003, using its proprietary patented technology, Gemoscan
develops, owns and markets comprehensive food sensitivity and dietary
management solutions for consumers, including the HEMOCODE™ Food Intolerance
System and the MenuWise™ Food Intolerance Plan, personalized naturopathically
supervised nutritional programs that promote well-being. Gemoscan is the first
and only provider to commercialize a food intolerance management solution
directly to consumers in partnership with retailers, and today offers the most
comprehensive services available.

Gemoscan Canada, Inc. trades its shares on the Toronto Venture Exchange under
the symbol GES and is quoted on the Munich, Frankfurt and Stuttgart Stock
Exchanges under the symbol 1GE.

Forward-Looking Information

This news release contains certain "forward-looking information". All
statements, other than statements of historical fact that address activities,
events or developments that Gemoscan believes, expects or anticipates will or
may occur in the future. These forward-looking statements reflect the current
expectations or beliefs of Gemoscan based on information currently available
to Gemoscan. Forward-looking statements are subject to a number of significant
risks and uncertainties and other factors that may cause the actual results of
Gemoscan to differ materially from those discussed in the forward-looking
statements, and even if such actual results are realized or substantially
realized, there can be no assurance that they will have the expected
consequences to, or effects on Gemoscan. Any forward-looking statement speaks
only as of the date on which it is made and, except as may be required by
applicable securities laws, Gemoscan disclaims any intent or obligation to
update any forward- looking statement, whether as a result of new information,
future events or results or otherwise. Although Gemoscan believes that the
assumptions inherent in the forward-looking statements are reasonable,
forward-looking statements are not guarantees of future performance and
accordingly undue reliance should not be put on such statements due to the
inherent uncertainty therein.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.

CONTACT: Brian Kalish
         Chief Executive Officer
         Gemoscan Canada, Inc.
         416.650.1200
         bkalish@hemocode.com
         www.gemoscan.com
        
         Media:
        
         Leonard Zehr
         Kilmer Lucas Inc.
         T: (416) 833-9317
         leonard@kilmerlucas.com